Potential New Applications of Sodium–Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular Toxicity

Potential New Applications of Sodium–Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular Toxicity

Sodium–glucose cotransporter-2 inhibitors (SGLT2i), initially developed for the management of type 2 diabetes mellitus, have demonstrated significant nephroprotective and cardioprotective effects. These benefits have led to their inclusion in heart failure (HF) management guidelines, irrespective of...

Full description

Saved in:
Bibliographic Details
Main Authors: Agnieszka Maria Zebrowska, Anna Borowiec
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Pharmaceuticals
Subjects:
sodium–glucose cotransporter-2 inhibitors
cardiotoxicity
cancer therapy-related cardiac dysfunction
cancer therapy-related cardiovascular toxicity
anthracycline-induced cardiotoxicity
cardioprotection
Online Access:https://www.mdpi.com/1424-8247/18/6/857
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items